Effective Daily Care for Atopic and Eczema Prone Skin

The AT4 System, first introduced in Spain by LETI Laboratories more than 15 years ago, is now available to US healthcare providers for the daily care of atopic and eczema prone skin. The system was formulated as a “clinical companion” to prescribed treatments for the comprehensive management of atopic skin. The system includes 4 non-prescription, steroid-free products:

1. Extra-gentle hygiene: Lipid Repair Bath Gel

2. Daily care: Soothing Body Lotion (daily emollient, especially post-bathing)

3. Daily care: Daily Defense Facial Moisturizer (for delicate facial skin)

4. Intensive emollient: A.D. Intensive Cream — designed as a coadjuvant to prescribed treatments during flare-ups

AT4 System Concept

Atopic dermatitis (AD) is characterized by 4 main concerns: dry skin, pruritus/itch, inflammation and irritation and microbial imbalance.Each non-prescription, steroid-free product in the AT4 line was carefully formulated to address these concerns by providing effective hydration, a calming/soothing effect, protecting from external irritants and promoting a healthy balance of surface flora.

Emollients as First-Line Treatment

The therapeutic goals for treating atopic dermatitis are to: 1) reduce the impact of symptoms, 2) increase time between flares and 3) shorten duration of flares when they occur. To accomplish this, a mix of daily care and episodic treatments are often required.

Effective management strategies are multifaceted and include prescribed medications, emollients and even education with avoidance and environmental control measures. Importantly, the use of emollients is recommended as first-line treatment for AD of all severities.1

A substantial body of evidence highlights the importance of emollient use. For example, a study of emollient use in children has been shown to significantly improve symptoms during corticosteroid treatment of AD and to maintain clinical improvement after therapy discontinuation.2 However, compliance and patient understanding about the importance of emollient use is very low — perhaps lower than 5%. Fortunately, when healthcare professionals provide a very basic level of instruction and dispense emollients as part of a management plan, usage and outcomes improve rapidly. In 1 study, eczema severity was reduced by 89% and emollient use increased 800%.3,4

These data suggest that a patient’s daily care regimen is clinically important and most effective under a clinician’s guidance. For this reason, DermWORX makes the AT4 System available exclusively to healthcare professionals for their patients. This provides clinicians with comprehensive control over the entire management plan, rather than managing only the prescription medications and leaving patients to fend for themselves in the skincare aisle at the local pharmacy or supermarket. 

References

1. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-299.e1-17.

2. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19(7):614-618.

3. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149(3):582-589.

4. Mason JM, Carr J, Buckley C, et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC. 2013;13:7.

 

Go to page 2 for the clinical evidence supporting the use of 1 product in the AT4 line — A.D. Intensive Cream to be used as a coadjuvant emollient during times of acute dryness.



Select Page:     Next ->